RecruitingNot Applicable

Proactive Risk Evaluation for Cardiac Implantable Electronic Device Strategy Using AI-ECG

Taiwan11,492 participantsStarted 2025-11-01

Plain-language summary

The goal of this clinical trial is to learn whether an artificial intelligence-enhanced electrocardiogram (AI-ECG) strategy improves timely intervention of patients requiring cardiac implantable electronic devices (CIEDs), compared with standard clinical care.

Who can participate

Age range65 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * At least one 12-lead ECG within 1 year Exclusion Criteria: * Diagnosis of sick sinus syndrome * Diagnosis of high-grade or complete atrioventricular block * Diagnosis of ventricular tachycardia or ventricular fibrillation * Post CIED implant * Heart rate below 40 beats per minute by 12-lead ECG

What they're measuring

CIED implantation

Timeframe: Within 180 days after randomization

Trial details

NCT IDNCT07217236

SponsorNational Defense Medical Center, Taiwan

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-10-31

Contact for this trial

Chin Lin

+886-2-8792-3100 xup6fup0629@gmail.com

View on ClinicalTrials.gov More Artificial Intelligence (AI) trials